AOCI at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.
The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about CRISPR Therapeutics's aoci.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is CRISPR Therapeutics's AOCI?
- CRISPR Therapeutics (CRSP) reported AOCI of -$1.94M in Q1 2026.
- How has CRISPR Therapeutics's AOCI changed year-over-year?
- CRISPR Therapeutics's AOCI decreased by 146.9% year-over-year, from $4.14M to -$1.94M.
- What is the long-term trend for CRISPR Therapeutics's AOCI?
- Over 5 years (2020 to 2025), CRISPR Therapeutics's AOCI has grown at a 125.3% compound annual growth rate (CAGR), from -$83K to $4.82M.
- What does AOCI mean?
- Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.